Monographie - Caffeine citrate - Stabilis 4.0

Son güncelleme :
03/05/2024

Solunum stimülanı

Caffeine citrate

Enjeksiyon

Oral solüsyon / oral çözelti

Çözeltilerin stabilitesi

Karışımlardaki stabilitesi

Stabiliteyi etkileyen faktörler

Uyumluluk

Uygulama yöntemi

Kaynaklar

Pdf

Kimyasal yapı

Ticari isim

Ticari isim

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cafcit	Amerika Birleşik Devletleri
Cafeina 25% Bioquim	Arjantin
Cafeina citrato	İspanya
Cafeina Fada	Arjantin
Cafeine citrate Biomed	Yeni Zelanda
Cafeine Sterop	Belçika
Cafeinnova	Kolombiya
Caffeinospire	Mısır
Cafirate	Hindistan
Citrate de caféine Cooper	Fransa
Peyona oral y para perfusion	İspanya
Peyona oral/parenteral	Almanya, Romanya, Türkiye

Kaynaklar

Enjeksiyon

Kaynaklar : Caffeine citrate

	Tip	Yayın
43	Dergi	Fraser BD, Berod T, Whitney HAK. Stability of caffeine citrate injection in polypropylene syringes at room temperature. Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318	Dergi	Donnelly RF, Tirona RG. Stability of citrated caffeine injectable solution in glass vials. Am J Hosp Pharm 1994 ; 51: 512-514.
691	Dergi	Nahata MC, Zingarelli JR, Durell DE. Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions. J Clin Pharm Ther 1989 ; 14: 53-55.
1802	Dergi	Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087	Dergi	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
3379	Dergi	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3644	Laboratuar	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3976	Dergi	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319	Dergi	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4389	Dergi	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4419	Dergi	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543	Dergi	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4603	Dergi	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Dergi	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Mentions Légales